Clinical Trial Update: Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing nivolumab, ipilimumab, and short-course radiotherapy in adults with MGMT-unmethylated glioblastoma; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Radiotherapy
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: NYU Langone Health | Conditions: MGMT-unmethylated Glioblastoma (GBM), GBM | Phase 2 | Status: COMPLETED | Results posted: 2022-07-01